Brussels, 28/10/2002 (Agence Europe) - The European Parliament's vote on the medicines package has given rise to a rather lukewarm response reflecting the broad balance of the outcome in the favour of patients aiming to give some priority to public health rather than economic interests. As reported on 24 October, p.12, the EP also managed to strike a balance between the divergent interests of innovative laboratories and the manufacturers of generic drugs, giving the former ten year...